Vitamin D is included, along with thyroid and steroid hormones, within the unique category of endocrine molecules that act through nuclear receptors. Differently from its partners, until recently vitamin D was thought to be a specialized hormone with an action limited to the control of mineral and bone metabolism.
Vitamin D is included, along with thyroid and steroid hormones, within the unique category of endocrine molecules that act through nuclear receptors. Differently from its partners, until recently vitamin D was thought to be a specialized hormone with an action limited to the control of mineral and bone metabolism. 1 The misconception has been recently reviewed after the recognition that the vitamin D receptor (VDR) as well as the cell machinery to synthesize the active hormone 1,25(OH) 2 D are largely distributed among most tissues and cells. Therefore, vitamin D can potentially modulate an ample diversity of systems and functions, including the cardiovascular system, energy metabolism, immune modulation and cell proliferation. 2 The new knowledge reinvigorated the interest to unveil the ideal levels of vitamin D to obtain osteomineral, as well as non-mineral health. The biochemical measurement of 25-hydroxivitamin D (25-OHD) is considered the best surrogate parameter to assess the status of vitamin D sufficiency. Until 2010, the cut-off point for 25-OHD serum levels was set at 15 ng/mL, and it was an uncommon laboratory parameter, seldom requested by a specialist. Since then, a passionate discussion emerged regarding one key point: what are the ideal serum levels of 25-OHD? Some authors have stated that they are the serum levels that are able to promote the intestinal absorption of calcium, stabilize parathyroid (PTH) serum levels and enable porper bone mineralization. However, this point is still a conundrum.
In a perfect world, the new knowledge would stimulate clinical investigation through long prospective studies, as well as randomized double-blinded studies to establish the ideal levels of vitamin D. Conversely, a new proposal was made based on previously published studies, most small and observational investigations, and the ideal serum levels of 25-OHD were set at 30 ng/mL. 6 Moreover, The Vitamin D Assessment Study, a randomized, double-blinded, placebo-controlled trial followed-up 5,108 individuals for 3 years, and oral vitamin D3 at an initial dose of 200,000 IU, followed a month later by monthly doses of 100,000 IU, were administered to half of the sample. The authors concluded that a monthly high-dose of vitamin D supplementation does not prevent cardiovascular disease. 7 Another arm of the same study observed that the highdose vitamin D 3 supplementation of 100.000 IU monthly over 2.5-4.2 years did not prevent falls or fractures in a healthy, ambulatory care, adult population. 8 Soon, other vitamin D randomized, double-blinded, placebo-controlled trials will be available, and they will provide appropriate scientific support for the potential of vitamin D to prevent different disorders and about the ideal serum levels of 25-OHD. Another important point related to this subject is the target population to be evaluated in the vitamin D measurement. Regarding this issue, there is a consensus among medical associations that there is no need to screen the general population routinely.
3,4,9 The US Prevention Service Task Force (USPSTF) issued a recommendation that the current evidence for screening for vitamin D deficiency in community-dwelling, non-pregnant, asymptomatic adults 18 years of age to improve health outcomes is insufficient. Moreover, the USPSTF stated that the balance between the benefits and harms of screening and early intervention cannot be determined. 10 The
American Congress of Obstetricians and Gynecologists, the American Geriatric Society, and the National Osteoporosis Foundation recommend testing for vitamin D as part of osteoporosis management or to prevent falls. The Endocrine Society It is unnecessary to observe that the aforementioned list will soon have to be revised and most likely shortened. Therefore, not only the reference values of vitamin D have to be thoroughly scrutinized, but the population at risk for hypovitaminosis D has to be better defined. There is a consensus that it is not necessary to screen the general population routinely. In the same line, there is no scientific support to link vitamin D with benefits in non-mineral outcomes such as in the cases of diabetes mellitus, cancer and death. Moreover, it is necessary to call attention to the fact that no medical association or institution has labeled menopause as a clinical risk for vitamin D deficiency.
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